Ability Biologics Closes $12M Seed Funding
Summary
The company intends to use the funds to continue to develop its solutions. Launched by Amplitude Ventures, working with co-founders Giles Day, CEO, and Jean-Philippe Bürckert, Vice President of Technology, Ability will use its AbiLeap™ discovery engine to systematically generate logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics. The AbiLeap™ discovery engine combines an Artificial Intelligence (AI) platform with a large database of antibody-antigen interactions, bringing together more than five years of discovery data, incorporating both public and private data sources. This allows the company to address a longstanding challenge by generating fully human antibodies that are logic-gated, enabling them to target specific tissues and cells based on the local microenvironment dictated by conditions such as pH, temperature, or the presence of certain metabolites. Ability has already established a partnership with Charles River Laboratories, a global provider of drug discovery and non-clinical development solutions.